

1/16





FIG. 1A



g1ZD-GFP

env	IRES
...AGAGTACGAGCC TAG ATAACGTTACTGGCC...	
IRES	GFP
...CACGATAATACC ATG GCCATTGAAACAAAGG...	
GFP	MLV NONCODING
...CTGTACAAG TAG CGGCCGCGCCATAGATAAAA...	

g1ZD-hygro

env	IRES
...AGAGTACGAGCC TAG ATAACGTTACTGGCC...	
IRES	hygromycin R
...CACGATAATACC ATG GCCATTGAAACCGCGA...	
hygromycin R	MLV NONCODING
...TGGGGGCCGCGCC TAG ATAAAAATAAAAGAT...	

FIG. 1B

2/16




FIG. 2A






FIG. 2B

3/16

**FIG. 3A****FIG. 3B**

4/16




FIG. 4

5/16




FIG. 5





FIG. 6A



6/16





FIG. 6B

7/16

Negative Control group

Experimental group

RAT NMU BREAST CANCER CELL INJECTION
(INITIAL INOCULUM: 2×10^6 CELLS)



8/16





FIG. 8

9/16



10/16




FIG. 9B

11/16




FIG. 10

12/16




FIG. 11

13/16




FIG. 12




FIG. 12

14/16




FIG. 14





FIG. 15

15/16




FIG. 16A





FIG. 16B

16/16

ZE-GFP



ZV-A-GFP





FIG. 17

WILD TYPE MLV ENVELOPE



ZDAH-emd



ZBAH-emd



FIG. 18